Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

BACKGROUND: The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in anim...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Myron J., Ustianowski, Andrew, De Wit, Stéphane, Launay, Odile, Avila, Miles, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Ellery, Adam, Levinson, Dennis J., Ambery, Philip, Arends, Rosalinda H., Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J., Koh, Gavin C.K.W., Near, Karen A., Padilla, Kelly W., Psachoulia, Konstantina, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N., Esser, Mark T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069994/
https://www.ncbi.nlm.nih.gov/pubmed/35443106
http://dx.doi.org/10.1056/NEJMoa2116620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069994/
https://www.ncbi.nlm.nih.gov/pubmed/35443106
http://dx.doi.org/10.1056/NEJMoa2116620

Ejemplares similares